Trial Profile
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 11 Dec 2023
Price :
$35
*
At a glance
- Drugs Numidargistat (Primary) ; Cisplatin; Fluorouracil; Folinic acid; Gemcitabine; Oxaliplatin; Paclitaxel
- Indications Adenocarcinoma; Biliary cancer; Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Gastric cancer; Oesophageal cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Incyte Corporation
- 22 Dec 2022 Status changed from active, no longer recruiting to completed.
- 20 Jul 2022 Planned primary completion date changed from 30 Jun 2022 to 30 Dec 2022.
- 24 Jun 2022 Planned End Date changed from 30 Jun 2022 to 30 Dec 2022.